MedTrace Logo

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

NCT02551172 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2015-09-16

No results posted yet for this study

Summary

To investigate the efficacy and safety after administration of HCP1105 in hyperlipidemic patients with high risk for CHD.

Conditions

  • Hyperlipidemias

Interventions

DRUG

HCP1105

Rosuvastatin + Omega-3-acids ethyl esters

DRUG

HGP0816

Rosuvastatin

DRUG

Placebo of HCP1105

Soybean Oil

DRUG

Placebo of HGP0816

Exclusion of Rosuvastatin in HGP0816

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Jung-yeol Park, M.D., Ph.D. · Asan Medecal Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-01-31
Completion
2016-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02551172 on ClinicalTrials.gov